A

Alphatec Spine

Develops and markets spinal surgery solutions

Supplier Quality Engineer 3

Full-Time
$110k - $125k/yr
Mid, Senior, Expert
Bachelor's
Carlsbad, CA, USA
In PersonTravel of approximately 10–30% is required.
Manufacturing Quality & TestQuality Engineering
No H1B Sponsorship

About the job

Requirements
  • Medical device industry experience is required.
  • Strong understanding of FDA 21 CFR Part 820, ISO 13485, MDSAP, ISO 14971, and purchasing controls.
  • Lead Auditor certification or demonstrated ability to independently lead supplier audits.
  • Experience leading supplier audits, supplier assessments, Supplier Corrective Action Requests, supplier nonconformances, and supplier quality investigations.
  • Strong knowledge of Statistical Process Control, Design of Experiments, Gage R&R, process capability, root cause analysis, manufacturing process validation, mechanical inspection, and Geometric Dimensioning and Tolerancing.
  • Ability to read, analyze, and interpret blueprints using ASME Y14.5 Geometric Dimensioning and Tolerancing principles.
  • Ability to communicate effectively with suppliers regarding nonconformances, Supplier Corrective Action Requests, containment, root cause, corrective action, objective evidence, and effectiveness checks.
  • Ability to develop and maintain strong working relationships with internal and external customers and suppliers.
  • Ability to solve complex problems to root cause and prevent recurrence.
  • Strong technical writing skills for reports, procedures, audit records, supplier communications, and quality documentation.
  • Ability to execute plans and strategies to completion with minimal management oversight.
  • Ability to travel approximately 10–30% as required.
  • A bachelor's degree from a four-year college or university in Engineering or a related technical discipline, or equivalent experience.
  • Typical experience range is 4–15 years in quality engineering, supplier quality, manufacturing engineering, or a regulated manufacturing environment.
Responsibilities
  • Lead supplier quality activities, including supplier performance management, issue resolution, supplier development, and continuous improvement initiatives.
  • Develop and maintain strategic relationships with assigned suppliers while serving as the primary quality contact.
  • Lead supplier qualification, requalification, classification, and supplier development activities.
  • Evaluate supplier quality system effectiveness and manufacturing process controls using risk-based decision-making principles.
  • Drive supplier performance improvement initiatives supporting quality, delivery, compliance, and operational excellence objectives.
  • Support Approved Supplier List strategy and supplier risk management activities.
  • Serve as Lead Auditor and regularly conduct supplier quality system and process audits.
  • Develop supplier audit plans, audit reports, audit finding responses, and effectiveness reviews.
  • Lead supplier audit finding closure, corrective action follow-up, and verification of effectiveness.
  • Represent Supplier Quality during internal audits, external audits, and regulatory inspections.
  • Lead complex Supplier Corrective Action Requests from initiation through effectiveness verification.
  • Lead supplier-related nonconformance investigations, containment activities, disposition strategies, and corrective action implementation.
  • Facilitate structured root cause investigations using 8D, DMAIC, Fishbone, Fault Tree Analysis, and 5 Why analysis.
  • Lead difficult supplier discussions and quality escalations while maintaining productive supplier relationships.
  • Independently manage complex supplier quality issues with minimal management support.
  • Lead Supplier Change Request reviews, ensuring appropriate risk assessment and cross-functional evaluation.
  • Lead supplier-specific process Failure Mode and Effects Analyses and supplier process risk assessments.
  • Evaluate the impact of supplier changes on product quality, validation status, regulatory compliance, and business continuity.
  • Develop risk mitigation plans for critical suppliers, processes, and commodities.
  • Partner regularly with Strategic Supply Chain and Purchasing teams to support sourcing decisions and supplier strategies.
  • Lead supplier business reviews and supplier quality performance reviews.
  • Develop supplier improvement roadmaps focused on capability, capacity, compliance, responsiveness, and quality performance.
  • Support new supplier onboarding, second-source development, and supplier transfer activities.
  • Lead supplier qualification activities, including process development, capability studies, process validation support, Gage R&R studies, correlation studies, and First Article activities.
  • Provide statistical leadership supporting supplier process controls and manufacturing improvements.
  • Support complaint investigations, design transfer activities, and post-market quality investigations involving suppliers.
  • Provide supplier quality input to New Product Development, Design Transfer, Manufacturing Readiness, and sustaining product activities.
  • Lead development, negotiation, implementation, and revision of supplier Quality Agreements.
  • Lead continuous improvement initiatives within Supplier Quality and assigned supplier areas.
  • Mentor Supplier Quality Engineers and Quality Engineers on auditing, supplier risk management, supplier investigations, and supplier development practices.
  • Share supplier lessons learned, quality trends, and best practices across Quality Engineering, Operations, Purchasing, and Supply Chain teams.
Desired Qualifications
  • ASQ Certified Quality Engineer certification.
  • ASQ Certified Quality Auditor certification.
  • Lead Auditor certification.
  • Strong working knowledge of the DMAIC/Six Sigma problem-solving process.

About the company

Alphatec Spine develops and sells implants, instruments, and integrated technologies for spine surgery, including devices used in fusion procedures and related navigation or imaging systems gained through acquisitions like SafeOp Surgical. During surgery, surgeons use these implants and instruments, often with imaging or navigation tools to plan and guide the procedure, while the implants support fusion and healing. It differentiates itself with a broad product portfolio and enhanced technology through strategic acquisitions, giving it capabilities in navigation and advanced spine solutions beyond a narrow line of implants. Its goal is to improve spinal surgery outcomes and expand access to effective spine-care solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Carlsbad, California

Founded

1990

Get referred to Alphatec Spine

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $213.5 million, up 15% year over year.
  • Adjusted EBITDA rose 53% to $36 million, lifting margin to 17%.
  • May 2026 refinancing extended maturities to 2031 and cut interest expense $6 million.

What critics are saying

  • May 2026 EOS revenue missed expectations; installations failed, triggering a 32% stock drop.
  • Kirby McInerney, Pomerantz, and others investigate potential securities fraud after the May 5 disclosure.
  • With $685 million debt, another EOS stall can force dilutive financing before 2030.

What makes Alphatec Spine unique

  • ATEC combines EOS imaging, Valence robotics, SafeOp neuromonitoring, and patient-specific planning.
  • Tommy Carls joined September 2026 to unify InformatiX across imaging, analytics, and surgery.
  • Its procedural ecosystem ties preoperative planning directly to intraoperative execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Paid Holidays

Disability Insurance

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

6%

2 year growth

6%
SPINEMarketGroup
Sep 24th, 2026
ATEC appoints Tommy Carls Executive Vice President, Data Intelligence and Strategy.

ATEC appoints Tommy Carls Executive Vice President, Data Intelligence and Strategy. Accomplished spine executive to advance ATEC's InformatiX strategy CARLSBAD, Calif.-(BUSINESS WIRE)-Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced that Thomas "Tommy" Carls has joined the company as Executive Vice President, Data Intelligence and Strategy. Carls will report directly to Chairman and Chief Executive Officer, Pat Miles, and will serve as a member of ATEC's Senior Leadership Team. In this newly created role, Carls will lead ATEC's development and marketing efforts across EOSedge, EOS Insight, data acquisition and analytics, and the broader InformatiX strategy. His mandate is to focus priorities, connect global teams and capabilities, and accelerate an integrated strategy that turns information about each patient and procedure into actionable clinical insight. "I have known and trusted Tommy for nearly 30 years," said Miles. "He has spent his career translating complex clinical needs into technologies that meaningfully advance spine surgery. Tommy is a student of spine. His depth of experience across implants, enabling technologies, imaging, software and clinical strategy makes him uniquely qualified to lead this next phase of our evolution. I am confident Tommy will help us accelerate the use of data and predictive analytics to make spine surgery better informed, more reproducible and personalized." ATEC has assembled a procedural ecosystem spanning EOS imaging, EOS Insight, surgical planning, Valence navigation and robotics, SafeOp neuromonitoring, and patient-specific solutions. By connecting those capabilities through InformatiX, ATEC intends to apply data and predictive analytics to inform decisions before, during and after surgery, improve the reproducibility of surgical execution, and create a learning system that advances spine care over time. Carls brings more than 3 decades of leadership and innovation experience in spine and medical technology. Throughout his career, Carls has helped develop and launch market-leading technologies across spinal implants, enabling technologies, image-guided surgery and robotics. He previously served as Vice President of Product and Clinical at Proprio Vision, where he helped advance an artificial intelligence-enabled surgical navigation platform. Before Proprio, Carls spent more than two decades with Sofamor Danek and Medtronic in numerous executive roles, spanning engineering, product development, marketing and global research and development. He holds more than 80 patents. Carls earned a Bachelor of Science degree in mechanical engineering from Tulane University and a Master of Business Administration from the University of Memphis. "ATEC has assembled a distinctive set of technologies across imaging, procedural planning, navigation and robotics, neuromonitoring, and patient-specific solutions," Carls said. "The opportunity is to connect those capabilities and apply data and predictive analytics, so a patient-specific plan becomes a shared source of truth across the continuum of care. This will inform better decisions, improve execution and create a learning system that advances outcomes over time. I am excited to join Pat and the high-performing ATEC team, to help bring that vision to life." About Alphatec Holdings Inc. ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC's Organic Innovation Machine(TM) is focused on developing new approaches that integrate seamlessly with the Company's expanding InformatiX(TM) platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC's vision is to be the Standard Bearer in Spine. For more information, visit www.atecspine.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Forward-looking statements include, among other things, statements regarding the Company's strategy; the integration of its technologies, teams and capabilities; the use of data and predictive analytics; and the anticipated clinical or commercial benefits of its InformatiX platform and procedural ecosystem. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Important factors include the Company's ability to execute its strategic operating plan, develop and integrate new products and technologies, obtain and maintain regulatory clearances or approvals, achieve surgeon acceptance, protect intellectual property, manage product liability and litigation exposure, and address other risks described in the Company's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contacts. Investor and Media Contact Robert Judd Investor Relations (760) 494-6790 [email protected]

Business Wire
Sep 23rd, 2026
ATEC appoints Tommy Carls to lead data intelligence and InformatiX strategy

Alphatec Holdings has appointed Tommy Carls as executive vice president of data intelligence and strategy. Carls will report to chief executive officer Pat Miles and join the company's senior leadership team. In this newly created role, Carls will lead ATEC's development and marketing efforts across EOSedge, EOS Insight, data acquisition and analytics, and the broader InformatiX strategy. His focus will be connecting global teams and turning patient and procedure information into actionable clinical insight. Carls brings over 30 years of experience in spine and medical technology. He previously served as vice president of product and clinical at Proprio Vision and spent more than two decades at Sofamor Danek and Medtronic. He holds more than 80 patents.

Yahoo Finance
Sep 14th, 2026
Alphatec surges 19.7% on Q2 results, expects $882M revenue for 2026

Alphatec shares surged 19.7% to $10.58, driven by investor optimism following strong second-quarter 2026 results. The medical equipment company reported earnings per share of 7 cents and revenues of $213.5 million for the quarter. The company maintains its full-year 2026 revenue guidance of approximately $882 million, supported by strong case volume growth, increased surgeon adoption, expanding profitability and positive free cash flow generation. For the upcoming quarter, Alphatec expects earnings of $0.11 per share, representing a 266.7% year-over-year increase. Revenues are projected at $224.28 million, up 14.1% from the prior year. However, the consensus earnings estimate has remained unchanged over the past 30 days. The stock currently carries a Zacks Rank #3 (Hold).

Yahoo Finance
Aug 5th, 2026
Alphatec delivers $214M revenue and 53% adjusted EBITDA growth despite biologics headwinds

Alphatec Holdings reported strong Q2 2026 results with total revenue of $214 million, up 15% year-over-year, and surgical revenue of $196 million, up 17%. The medical device company saw adjusted EBITDA rise 53% to $36 million, with margins expanding 420 basis points to 17%. The company added 24% more net new surgeons and posted 20% case volume growth. Gross margin improved 260 basis points to 72.5%, driven by better inventory efficiency and favourable product mix. Alphatec generated positive free cash flow of approximately $1 million in Q2 and raised full-year adjusted EBITDA guidance to $140 million from $134 million previously. However, revenue per case declined 2.7% due to case mix shifts and international growth. The company now expects full-year revenue per case to decline in the low single digits, citing slower biologics attachment improvement.

Yahoo Finance
Jun 11th, 2026
Alphatec grows revenue 25% to $764M but posts $143M loss with 17.2x debt-to-equity ratio

Alphatec, a spine surgery technology company, reported revenue of $764.2 million in FY 2025, up 25% year-over-year, but posted a net loss of $143.4 million. The company's debt-to-equity ratio stands at approximately 17.2x, whilst its current ratio is 2.1x. Stock-based compensation represented roughly 163% of operating cash flow. Inspire Medical Systems specialises in neurostimulation therapy for obstructive sleep apnea patients who cannot use standard breathing machines. The company targets sleep specialists and ENT surgeons globally. Alphatec differentiates itself through an integrated ecosystem using subsidiaries like EOS imaging and SafeOp Surgical, serving primarily the US hospital market whilst expanding into Europe and Japan. Both companies operate in medical technology but represent different maturity levels and financial profiles for investors seeking healthcare device exposure.